glp 1 ckd GLP1 Receptor Agonists vs SGLT2-I in Preventing in T2DM: An Interview – AJKD Blog Repurposing Diabetes Therapies in CKD:

Description

Nevertheless, current evidence supports GLP-1 RAs and multi-agonist formulations as highly promising pharmacotherapies that address the complex, multifactorial pathophysiology of MASLD while simultaneously improving cardiometabolic comorbidities, positioning them as cornerstone treatments in the evolving therapeutic landscape for this prevalent and burdensome disease

Treat this citation as unconfirmed until the brand provides the specific study reference

Cardiovascular benefit for GLP-1RAs was shown in 2016 for liraglutide in the LEADER trial and semaglutide in the SUSTAIN 6 trial

Tip: Purchase one 10 oz bottle of liquid magnesium citrate to use IN CASE your prep is not going as well as expected, especially if you suffer from occasional or frequent constipation